Gallbladder Carcinoma in the United States: A Population Based Clinical Outcomes Study Involving 22,343 Patients from the Surveillance, Epidemiology, and End Result Database (1973–2013)
Table 2
Demographics and clinical profile of 22,343 patients with gallbladder carcinoma from the Surveillance, Epidemiology, and End Result (SEER) database (1973–2013).
Variables
Frequency (%)
22,343
Age, years (mean ± SD)
71.17 ± 12.534
Gender, (%)
Male
6,549 (29.3%)
Female
15,794 (70.7%)
Region, (%)
Alaska
46 (0.2%)
East
6,684 (29.9%)
Northern Plains
4,230 (18.9%)
Pacific Coast
9,605 (43.0%)
Southwest
1,778 (8.0%)
Race, (%)
Caucasian
14,280 (64.0%)
African American
2,056 (9.2%)
Hispanic
3,740 (16.8%)
Asian/Pacific Islander
1,861 (8.3%)
American Indian/Alaska Native
375 (1.7%)
Grade, (%)
Well differentiated
2,252 (15.3%)
Moderately differentiated
5,619 (38.2%)
Poorly differentiated
6,238 (42.5%)
Undifferentiated
592 (4.0%)
Lymph node involvement, (%)
Yes
15,791 (88.2%)
No
2,105 (11.8%)
Treatment received, (%)
No treatment
6,811 (31.8%)
Surgery only
11,769 (55.0%)
Radiation only
545 (2.6%)
Both surgery and radiation
2,269 (10.6%)
Actuarial survival, years (mean ± SE)
2.715 ± 0.061
Actuarial survival by treatment, years (mean ± SE)
No treatment
0.618 ± 0.049
Surgery only
3.685 ± 0.093
Radiation only
0.815 ± 0.075
Both surgery and radiation
4.029 ± 0.184
Actuarial survival by grade, years (mean ± SE)
Well differentiated
5.926 ± 0.266
Moderately differentiated
3.720 ± 0.151
Poorly differentiated
1.664 ± 0.073
Undifferentiated
1.293 ± 0.167
Overall mortality, (%)
19,439 (87.0%)
Cancer specific mortality, (%)
16,856 (75.4%)
Cumulative survival, %
3-month
66%
6-month
50%
9-month
41%
1-year
34%
2-year
22%
3-year
17%
4-year
14%
5-year
13%
= number; SD = standard deviation; SE = standard error; data presented for patients with available information only.
